

# A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

NCT05583942

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Northwell Health
Enrollment	10 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Steroid Resistant Nephrotic Syndrome- defined as lack of remission after 4 weeks of therapy of prednisolone/prednisone at standard dose<sup>1</sup>
  - Age 3-17 years
  - eGFR  $\geq 30$  ml/min/1.73 m<sup>2</sup> (by modified Schwartz formula)
  - MCD or FSGS diagnosis (per biopsy)
  - Urine protein:creatinine (UPC) greater than 1.0
- ... and 4 more (see full listing online)

### Exclusion (8)

- Secondary causes of nephrotic syndrome (e.g. genetic, congenital, infectious)
  - Steroid sensitive nephrotic syndrome
  - History of genetic defects known to directly cause nephrotic syndrome (i.e., NPHS2 [podocin], NPHS1 [nephrin], PLCE1, WT1, or other known genetic cause)
  - Any known inflammatory condition
  - History of cardiac disease (arrhythmias, structural/functional abnormalities)
- ... and 3 more (see full listing online)

## Locations (2 total)

---

Cohen Children's Medical Center, New Hyde Park, New York, United States  
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

---

<https://clinicaltrials.gov/study/NCT05583942>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).